NCT06955481

Brief Summary

The purpose of this PMCF study is to demonstrate the accuracy of navigation using the new pheno4uTKA Level 1 software for OrthoPilot Elite® and to evaluate its safety and performance. Patient-related outcome measures (PROM) will be acquired to investigate functional outcome and patient satisfaction.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for all trials

Timeline
25mo left

Started Oct 2025

Typical duration for all trials

Geographic Reach
2 countries

4 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress22%
Oct 2025Jun 2028

First Submitted

Initial submission to the registry

April 25, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

May 2, 2025

Completed
5 months until next milestone

Study Start

First participant enrolled

October 7, 2025

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2027

Expected
11 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2028

Last Updated

November 17, 2025

Status Verified

November 1, 2025

Enrollment Period

1.7 years

First QC Date

April 25, 2025

Last Update Submit

November 14, 2025

Conditions

Keywords

NavigationTotal Knee ArthroplastyOrthoPilot

Outcome Measures

Primary Outcomes (1)

  • Comparison of the surgical accuracy between the new OrthoPilot Software and the previous OrthoPilot Software

    The primary variable delta (aHKA), is defined as the difference in the arithmetic hip-knee-angle (aHKA) between the 3 months postoperative and the intraoperatively planned value. The aHKA is calculated as the difference of the mechanical medial proximal tibial angle (MPTA) and the mechanical lateral distal femoral angle (LDFA), both measured in degrees.

    3 months post OP

Secondary Outcomes (8)

  • Implant survival

    ongoing, up to 2 years follow-up

  • Oxford Knee Score (OKS)

    Preoperative,3 months-, 12 months and 2 years post operative

  • Forgotten Joint Score (FJS)

    Preoperative,3 months-, 12 months and 2 years post operative

  • Quality of Life (EQ-5D-5L)

    Preoperative, Postoperative 3 Months + /- 6 weeks, Postoperative 12 months + /- 6 weeks, Postoperative 2 year + /- 3 months

  • NET Promotor Score (NPS)

    Postoperative 3 Months + /- 6 weeks, Postoperative 12 months + /- 6 weeks, Postoperative 2 year + /- 3 months

  • +3 more secondary outcomes

Study Arms (1)

pheno4u TKA Level 1

Navigation of TKA (Total Knee Arthroplasty) using the new pheno4uTKA Level 1 software for OrthoPilot Elite®.

Procedure: Navigated Total Knee Arthroplasty

Interventions

The OrthoPilot® Software Pheno4u TKA Level 1 is an application software for computer aided navigation of surgical instruments and serves (in combination with compatible hardware and compatible navigated instruments) as an optional aid for the surgeon during the preparation of the implant site for a compatible knee endoprosthesis.

pheno4u TKA Level 1

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients between 18 and 80 years of age having indication for a fixed-bearing total knee endoprosthesis, without retropatellar arthrosis requiring patella resurfacing

You may qualify if:

  • Indication for a TKA with the OrthoPilot® Navigation System with a Aesculap total knee endo-prosthesis
  • Written signed informed consent of patient
  • Willingness and mental ability to participate at the long-term follow-up examinations

You may not qualify if:

  • Pregnancy
  • Patients \< 18 years or \> 80 years
  • Patients unable to participate at the follow-up examination (physically, mentally)
  • Previous joint replacement at the index knee
  • ASA classification \> 3 ( ASA I: A healthy patient without systemic diseases. ASA II: A patient with a mild systemic disease that is well controlled (e.g., well-controlled diabetes or hypertension). ASA III: A patient with a severe systemic disease that causes functional limitations (e.g., poorly controlled diabetes, COPD). ASA IV: A patient with a life-threatening systemic disease (e.g., severe heart failure, sepsis). ASA V: A dying patient who is not expected to survive without the operation. ASA VI: A deceased patient whose organs are being removed for donation.)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

Šumperk Hospital Inc.

Šumperk, 78701, Czechia

NOT YET RECRUITING

Klinikum Konstanz GmbH

Konstanz, Baden-Wurttemberg, 78464, Germany

NOT YET RECRUITING

Park-Klinik Weißensee

Berlin, 13086, Germany

RECRUITING

Universitätsklinikum Carl Gustav Carus

Dresden, 01307, Germany

NOT YET RECRUITING

MeSH Terms

Conditions

Osteoarthritis, KneeJoint Diseases

Condition Hierarchy (Ancestors)

OsteoarthritisArthritisMusculoskeletal DiseasesRheumatic Diseases

Study Officials

  • Jörg Lützner, Prof. Dr.

    Universitätsklinikum Carl Gustav Carus

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Heike Oberascher

CONTACT

Stefan Maenz, Dr.

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 25, 2025

First Posted

May 2, 2025

Study Start

October 7, 2025

Primary Completion (Estimated)

July 1, 2027

Study Completion (Estimated)

June 1, 2028

Last Updated

November 17, 2025

Record last verified: 2025-11

Locations